

UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC.  
Petitioner,

v.

NOVARTIS PHARMA AG,  
NOVARTIS TECHNOLOGY LLC,  
NOVARTIS PHARMACEUTICALS CORPORATION,  
Patent Owners.

Patent Number: 9,220,631

**DECLARATION OF HORST KOLLER**

## TABLE OF CONTENTS

	Page
I. Introduction	<del>1</del> <u>1</u>
II. Summary of Opinions	1
III. Qualifications and Compensation	3
IV. Relevant Legal Standards	<del>7</del> <u>9</u>
A. Claim Construction	<del>8</del> <u>10</u>
B. Invalidity	<del>9</del> <u>11</u>
C. Person of Ordinary Skill in the Art	<del>12</del> <u>14</u>
V. Background of the Technology	<del>14</del> <u>16</u>
A. Intravitreal Administration of VEGF Antagonists	<del>14</del> <u>16</u>
B. Pre-filled Syringes	<del>15</del> <u>17</u>
C. Syringe Stopper Forces	<del>20</del> <u>23</u>
D. Siliconization of Pre-filled Syringe Components	<del>24</del> <u>28</u>
1. “Oily” or “Spray-on” Siliconization	<del>26</del> <u>30</u>
2. “Baked-On” Siliconization	<del>30</del> <u>33</u>
3. Coated, Uncoated, and Siliconized Stoppers	<del>36</del> <u>40</u>
E. Sterilization of Pre-filled Syringes	<del>39</del> <u>44</u>
F. Particulate Content	<del>46</del> <u>53</u>
VI. The ‘631 Patent	<del>48</del> <u>55</u>
A. The Claims	<del>48</del> <u>55</u>
B. Overview of Specification	<del>52</del> <u>59</u>
1. The ‘631 patent fails to disclose a process for applying <del>low</del> <u>the claimed</u> levels of silicone oil	<del>52</del> <u>59</u>

2.	The '631 patent fails to disclose <del>the</del> process <u>details</u> for terminal sterilization	<del>53</del> <u>61</u>	
<u>C.</u>	<u>Prosecution History</u>	<u>64</u>	
<del>C.D.</del>	<del>Meaning of the</del> Claim <del>Terms</del> <u>Construction</u>	<del>53</del> <u>68</u>	
VII.	The Prior Art to the '631 Patent	<del>55</del> <u>70</u>	
A.	"Sigg" -WO 2011/006877	<del>55</del> <u>70</u>	
B.	"Lam" -International Pat. Appl. Pub. No. WO 2008/077155	<del>60</del> <u>76</u>	
C.	"Boulange" -International Pat. Appl. Pub. No. WO 2009/030976	<del>65</del> <u>81</u>	
D.	<del>"Reuter"-Bruno Reuter &amp; Claudia Petersen, Syringe Siliconization, 4 TechnoPharm 2, 238 (2012)</del> <u>2008 Macugen Label</u>	<del>71</del> <u>89</u>	
E.	"Fries" -A. Fries, <i>Drug Delivery of Sensitive Biopharmaceuticals with <del>prefilled</del> <u>Prefilled</u> Syringes</i> , Drug Delivery Technology, Vol. 9, No. 5	<del>77</del> <u>92</u>	
F.	"Furfine" -WO 2007/149334	<del>78</del> <u>93</u>	
<del>G.</del>	<del>"Macugen Label"-Macugen® Prescribing Information</del>	<del>78</del>	
VIII.	<del>Petition 1,</del> Ground 1: Sigg in View of Boulange Renders Obvious Claims <del>1-3,5-9, and</del> <u>1-3, 5-9,</u> 14-22	<del>79</del> <u>94</u>	
A.	Motivation to Combine Sigg and Boulange	<del>79</del> <u>94</u>	
1.	Silicone Oil and Break Loose / Slide Forces	<del>79</del> <u>94</u>	
2.	Particulate Content	<del>87</del> <u>101</u>	
<u>3.</u>	<u>Stopper Configurations</u>	<u>103</u>	
<u>B.</u>	<u>Reasonable Expectation of Success</u>	<u>111</u>	
<del>B.C.</del>	Claim <del>I</del>	<del>89</del> <u>1</u>	<u>116</u>
1.	[1.a] A pre-filled, terminally sterilized syringe for intravitreal injection	<del>89</del> <u>116</u>	
2.	[1.b] the syringe comprising a glass body forming a barrel, a stopper and a plunger	<del>90</del> <u>118</u>	
3.	[1.c] and containing an ophthalmic solution which comprises a VEGF-antagonist, wherein:	<del>92</del> <u>120</u>	

4.	[1.d] the syringe has a nominal maximum fill volume of between about 0.5 mL and about 1 mL	<del>93</del> <u>122</u>
5.	[1.e] the syringe barrel comprises from about 1 <del>µg</del> <u>µg</u> to 100 <del>µg</del> <u>µg</u> silicone oil	<del>95</del> <u>124</u>
6.	[1.f] the VEGF-antagonist solution comprises no more than 2 particles > 50 µm in diameter per mL	<del>96</del> <u>127</u>
7.	[1.g] and wherein the syringe has a stopper break loose force of less than about 11N	<del>99</del> <u>129</u>
<del>CD.</del>	Claims 2, 3, 5-9, <del>14, 16-22</del> and <del>24</del> <u>14-22</u>	<del>100</del> <u>132</u>
1.	Claim 2	<del>100</del> <u>132</u>
2.	Claims 3 and 22	<del>102</del> <u>133</u>
3.	Claims 5 and 6	<del>103</del> <u>134</u>
4.	Claims 7, 8, and 9	<del>103</del> <u>135</u>
5.	Claims 14 and 16	<del>104</del> <u>136</u>
6.	Claim 15	<del>106</del> <u>139</u>
7.	Claim 17	<del>109</del> <u>141</u>
8.	Claims 18 and 19	<del>110</del> <u>142</u>
9.	Claim 20	<del>112</del> <u>144</u>
10.	Claim 21	<del>114</del> <u>146</u>
IX.	<del>Petition 1,</del> Ground <del>23</del> <u>23</u> : Sigg in View of Boulange and Fries Renders Obvious Claims 4, 10, and 23	<del>H6</del> <u>148</u>
X.	<del>Petition 1,</del> Ground <del>35</del> <u>35</u> : Sigg in view of Boulange and Furfine Renders Obvious Claims 11-13	<del>H8</del> <u>151</u>
	<del>A. Claims 11 and 12</del>	<del>119</del>
	<del>B. Claim 13</del>	<del>120</del>
XI.	<del>Petition</del> <u>Ground 2,</u> <del>Ground I:</del> Lam in View of <del>Reuter</del> <u>Boulange</u> Renders Obvious Claims <del>1-10</del> <u>1-3, 59,</u> and <del>14-23</del> <u>14-22</u>	<del>121</del> <u>154</u>
A.	Motivation to Combine Lam and <del>Reuter</del> <u>121</u> <u>Boulange With a Reasonable Expectation of Success</u>	

	1.	Silicone Oil and Break Loose / Slide Forces	<del>121</del> <u>155</u>	
	2.	Particulate Content	<del>128</del> <u>157</u>	
B.	Claim <del>1</del>		<del>130</del> <u>159</u>	<u>159</u>
	1.	[1.a] A pre-filled, terminally sterilized syringe for intravitreal injection	<del>130</del> <u>159</u>	
	2.	[1.b] the syringe comprising a glass body forming a barrel, a stopper and a plunger	<del>132</del> <u>160</u>	
	3.	[1.c] and containing an ophthalmic solution which comprises a VEGF-antagonist, wherein:	<del>133</del> <u>161</u>	
	4.	[1.d] the syringe has a nominal maximum fill volume of between about 0.5 mL and about 1 mL	<del>134</del> <u>162</u>	
	5.	[1.e] the syringe barrel comprises from about 1 <del>µg</del> <u>µg</u> to 100 <del>µg</del> <u>µg</u> silicone oil	<del>134</del> <u>163</u>	
	6.	[1.f] the VEGF-antagonist solution comprises no more than 2 particles >50 µm in diameter per mL	<del>137</del> <u>163</u>	
	7.	[1.g] and wherein the syringe has a stopper break loose force of less than about 11N	<del>140</del> <u>166</u>	
C.	Claims <del>2-10</del> <u>2, 3, 5-9</u> , and <del>14-24</del> <u>14-22</u>		<del>142</del> <u>166</u>	
	1.	Claim 2	<del>142</del> <u>166</u>	
	2.	Claims 3 and 22	<del>142</del> <u>166</u>	
	<del>3.</del>	<del>Claims 4, 10, and 23</del>	<del>143</del>	
	<del>43.</del>	Claims 5 and 6	<del>144</del> <u>167</u>	
	<del>54.</del>	Claims 7, 8, and 9	<del>145</del> <u>167</u>	
	<del>65.</del>	Claims 14 and 16	<del>146</del> <u>168</u>	
	<del>76.</del>	Claim 15	<del>147</del> <u>168</u>	
	<del>87.</del>	Claim 17	<del>150</del> <u>169</u>	
	<del>98.</del>	Claims 18 and 19	<del>151</del> <u>170</u>	
	<del>109.</del>	Claim 20	<del>152</del> <u>172</u>	

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.